Clinical trial · Observational
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
NCT01339975CI-TRIAL-00039877ChemoRenCancompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research. The aim of this study is to evaluate the interest of CXCL4, CXCL4L1 and CXCR3 as biomarkers in localized, locally advanced or metastatic RCC. Indeed these chemokines have shown anti-angiogenic and anti-tumor properties in experimental models and may be particularly interesting for prognostic and predictive purposes.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma | Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Carcinoma Renal Cell | Renal Cell Carcinoma | ALIAS | 0.90 |
| Chemokines | — | UNRESOLVED | — |
| Kidney Diseases | — | UNRESOLVED | — |
| Kidney Neoplasms | Kidney Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological sample | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Group A. Surgically treated patients
- description
- Patients having a radical or partial nephrectomy.
- interventionNames
- Biological: Biological sample
- label
- Group B. Patients treated with targeted therapies
- description
- Patients treated by RCC-directed targeted therapy
- interventionNames
- Biological: Biological sample
Primary outcomes (1)
- measure
- Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3)
- timeFrame
- 3 years
- description
- Prognostic value of the markers of interest (CXCL4, CXCL4L1 et CXCR3) will be evaluated by the association of these markers with time to event occurrence. Localized or locally advanced renal cell carcinoma group: * local recurrence * contralateral recurrence * extra-renal distant recurrence (metastatic progression) * specific cancer death * nonspecific cancer death Metastatic renal cell carcinoma group : * local recurrence for patients who underwent a nephrectomy * contralateral reccurence * metastatic progression * specific cancer death * nonspecific cancer death
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients diagnosed with localized, locally advanced or metastatic Renal Cell Carcinoma : * having a radical or partial nephrectomy * or treated by RCC-directed targeted therapy * Patients who have signed and dated an informed consent form with the investigator Exclusion Criteria: * under 18 years old
References
Publications (22)
- BACKGROUNDBelot A, Grosclaude P, Bossard N, Jougla E, Benhamou E, Delafosse P, Guizard AV, Molinie F, Danzon A, Bara S, Bouvier AM, Tretarre B, Binder-Foucard F, Colonna M, Daubisse L, Hedelin G, Launoy G, Le Stang N, Maynadie M, Monnereau A, Troussard X, Faivre J, Collignon A, Janoray I, Arveux P, Buemi A, Raverdy N, Schvartz C, Bovet M, Cherie-Challine L, Esteve J, Remontet L, Velten M. Cancer incidence and mortality in France over the period 1980-2005. Rev Epidemiol Sante Publique. 2008 Jun;56(3):159-175. doi: 10.1016/j.respe.2008.03.117. Epub 2008 Jun 10. PMID 18547762
- BACKGROUNDRaynal G, Bernhard JC. [Premature death from urologic cancer: the kidneys at the forefront]. Prog Urol. 2007 Apr;17(2):260-1. doi: 10.1016/s1166-7087(07)92277-0. No abstract available. French. PMID 17489332
- BACKGROUNDMotzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40. doi: 10.1200/JCO.1999.17.8.2530. PMID 10561319
- BACKGROUNDMargulis V, Sanchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management. Cancer. 2007 May 15;109(10):2025-30. doi: 10.1002/cncr.22629. PMID 17420980
- BACKGROUNDMickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R; European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet. 2001 Sep 22;358(9286):966-70. doi: 10.1016/s0140-6736(01)06103-7. PMID 11583750
- BACKGROUNDMotzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007 Jan 11;356(2):115-24. doi: 10.1056/NEJMoa065044.